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Background: Adenocarcinoma of the lung with EML4-ALK translocation is a rare subtype of Non Small-Cell Lung
Cancer (NSCLC) that has recently shown to benefit from treatment with crizotinib. Despite the concerns about the
efficacy of crizotinib over cerebral metastases, some reports have described its activity, although always after local
treatment with radiotherapy. Recently it has been reported activity of crizotinib over choroidal metastases, again
after radiotherapy.
Case presentation: Herein we report a case of activity of crizotinib over choroidal metastases not previously
treated with radiotherapy.
Conclusion: We suggest crizotinib may be active over choroidal metastases in a patient harboring ALK
translocation with no need of radiotherapy.
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EML4-ALK-rearranged adenocarcinoma represents about
5-7% of Non Small Cell Lung Cancer (NSCLC). Treat-
ment for patients affected by metastatic adenocarcinoma
of the lung harbouring an EML4-ALK translocation is a
novel oral compound anti MET known as crizotinib [1]. It
is efficient on all sites of metastasis, except on cerebral
secondary lesions: this is possibly due to a possible poor
central nervous system (CNS) penetration.
Here we report a case of a patient with NSCLC adeno-
carcinoma, with ALK-rearrangement and bone, lymph
nodal and choroidal metastases at diagnosis, who showed
an impressive response to crizotinib in all sites.Case presentation
In August 2012, a 43-year-old man was hospitalized for
the sudden onset of visual impairment (left eye). He re-
ported not having had any traumas in the days before* Correspondence: abearz@cro.it
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unless otherwise stated.hospital admission, but referred having suffered for one
month from headache, mostly located in the left eye
area. He underwent a fluoroangiography, which showed
an extensive bullous exudative left retinal detachment
that involved the whole left retina, and was due to mul-
tiple, non-primitive, choroidal retinal neoplasias (Figure 1).
Computed Tomography (CT)-scan and Magnetic Reson-
ance Imaging of the brain showed the presence of abnor-
mal tissue in the right retina and in most part of the left
retina, where a clinically significant oedema was present.
Thorax CT-scan revealed a nodule in the right lung, in
the median lobe, with the enlargement of right medias-
tinal lymph nodes. Bronchoscopy diagnosed an adenocar-
cinoma of the lung. Bone scan showed the involvement of
several bones, cervical and dorsal vertebral bodies, and
sternum. Biopsy of the right lung lesion was performed
during bronchoscopy and an adenocarcinoma of the lung
was diagnosed. Genetic characterization showed the
presence of EGFR wild-type, KRAS wild-type, and EML4-
ALK rearrangement which were diagnosed by FISH. Clin-
ical TNM at the diagnosis was T2aN2M1, and distanttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Basal Fluorangiography, showing an extensive bullous essudative left retinal detachment.
Figure 2 Basal CT-scan of the eyes (A) and after 45 days on crizotinib (B), showing a reduction of the abnormal tissue in the left eye.
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Figure 3 Fluorangiography of the left eye, after 6 months in
crizotinib and 2 months after phacoemulsification with
lens implant.
Bearz et al. BMC Research Notes 2014, 7:589 Page 3 of 4
http://www.biomedcentral.com/1756-0500/7/589localizations were in the bone and bilateral choroids
mostly on the left eye.
The patient reported pain in his head, neck, dorsal
back region, and severe asthenia; he could only see a few
lights in his lower left visual field. He had been staying
in bed most of his daily time for one week. He started to
receive crizotinib 250 mg BID orally at the beginning of
October 2012. Treatment was well tolerated, with a few
G1 episodes of diarrhoea.
In a few weeks, symptoms improved with the reso-
lution of pain and asthenia, and the patient could finally
resume normal daily activities. Surprisingly, he reported
an improvement in his left eye, as demonstrated by the
comparison of basal CT-scan and CT-scan after 45 days
of treatment (Figure 2), and at the end of January 2013
he was admitted to eye surgery. The patient underwent
phacoemulsification with lens implant, 23 g vitrectomy
and an infusion of perfluorocarbon liquid (PFCL) to
smoothen the left retina. Endolaser was performed in
the superior temporal retina area; finally, ocular tampon-
ade with silicone oil 1000 cts was performed.
In the following months, the retina remained adherent
(Figure 3). However, the eyesight was limited to the
lower sector of the visual field for the presence of exuda-
tive lower mass with no signs of expansion, as well as
for the blurring caused by tamponade with silicone oil.
Nevertheless, patient started to drive again and began
a new job, thus resuming his normal daily activities.
CT-scans showed partial regression of the right lung
nodule, as well as of the mediastinal lymph nodes. Bone
scan revealed reduction of the previously evidenced ac-
tivity in the bone. After 15 months, CT-scans showed
signs of progression: while choroidal metastases were
stable, as well as bone metastasis, the nodule in the right
lung and the mediastinal lymph nodes showed a pro-
gression of about 21% according to RECIST criteria.Patient stopped treatment with crizotinib and switched to a
second-generation anti-ALK therapy (Alectinib, Roche),
thus obtaining a partial response of the lung nodule and
mediastinal lymph nodes two months later, still ongoing
after 7 months, and stabilization of the choroidal
metastases.Discussion and conclusions
Crizotinib is active against lung adenocarcinoma with
EML4-ALK translocation. However, the median length
of response duration is still unknown, as well as the effi-
cacy of crizotinib in reaching central nervous tissue. Sev-
eral reports showed the progression in central nervous
tissue, claiming a possible inefficacy of crizotinib to
overcome the central nervous barrier [1-3].
Nevertheless, at present there are only a few reports
on the crizotinib response to CNS metastases in the lit-
erature [4,5]. These cases had been pre-treated with
radiotherapy: this could explain the increase in blood–
brain barrier permeability, thus justifying the response,
or it is likely there might be a different benefit of crizo-
tinib in the CNS postiradiation as for other inhibitors
[6]. There is one report about choroidal metastases
responding to crizotinib, however, even in this case, both
choroids had previously been treated with radiotherapy
[7]. Our case describes for the first time a case of chor-
oidal metastases responding to crizotinib without previ-
ous radiotherapy. Choroidal metastases were reduced
with crizotinib and eyesight had improved. Our patient
had never received any radiotherapy; at the moment of
progression, the primary site tumor, e.g. the lung, had
increased, while choroidal metastases were still stable.
The blood–retinal barrier is required to maintain the
proper environment of neural retina controlling perme-
ability through the choroid capillaries and working as a
selective partition between the retina and the circulation
[8]. Based on our experience, we suggest that crizotinib
can reach choroidal metastases, possibly through the
fenestrated endothelium of choroidal vessels.Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing image. A copy of the written consent is available for
review by the Editor of this journal.
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